Global Blood Therapeutics Performance

GBTDelisted Stock  USD 68.49  0.00  0.00%   
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Global Blood are completely uncorrelated. Global Blood Therapeutics right now retains a risk of 0.0%. Please check out Global Blood rate of daily change , to decide if Global Blood will be following its current trending patterns.

Risk-Adjusted Performance

0 of 100

 
Low
 
High
Very Weak
Over the last 90 days Global Blood Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental drivers, Global Blood is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Quick Ratio7.33
Fifty Two Week Low21.65
Target High Price102.00
Fifty Two Week High73.02
Target Low Price31.00
  

Global Blood Relative Risk vs. Return Landscape

If you would invest  6,849  in Global Blood Therapeutics on December 30, 2023 and sell it today you would earn a total of  0.00  from holding Global Blood Therapeutics or generate 0.0% return on investment over 90 days. Global Blood Therapeutics is generating negative expected returns assuming volatility of 0.0% on return distribution over 90 days investment horizon. In other words, 0% of stocks are less volatile than Global, and above 99% of all equities are expected to generate higher returns over the next 90 days.
  Expected Return   
       Risk  

Global Blood Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Global Blood's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Global Blood Therapeutics, and traders can use it to determine the average amount a Global Blood's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
GBT
Based on monthly moving average Global Blood is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Global Blood by adding Global Blood to a well-diversified portfolio.

Global Blood Fundamentals Growth

Global Stock prices reflect investors' perceptions of the future prospects and financial health of Global Blood, and Global Blood fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Global Stock performance.

About Global Blood Performance

To evaluate Global Blood Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Global Blood generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Global Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Global Blood Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Global's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease . Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California. Global Blood operates under Biotechnology classification in the United States and is traded on NMS Exchange. It employs 457 people.

Things to note about Global Blood Therapeutics performance evaluation

Checking the ongoing alerts about Global Blood for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Global Blood Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Global Blood is not yet fully synchronised with the market data
Global Blood has a very high chance of going through financial distress in the upcoming years
The company reported the last year's revenue of 210.87 M. Reported Net Loss for the year was (309.58 M) with profit before taxes, overhead, and interest of 191.43 M.
Global Blood Therapeutics has about 553.42 M in cash with (249.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.5.
Over 97.0% of the company shares are owned by institutional investors
Evaluating Global Blood's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Global Blood's stock performance include:
  • Analyzing Global Blood's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Global Blood's stock is overvalued or undervalued compared to its peers.
  • Examining Global Blood's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Global Blood's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Global Blood's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Global Blood's stock. These opinions can provide insight into Global Blood's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Global Blood's stock performance is not an exact science, and many factors can impact Global Blood's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Note that the Global Blood Therapeutics information on this page should be used as a complementary analysis to other Global Blood's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Consideration for investing in Global Stock

If you are still planning to invest in Global Blood Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Global Blood's history and understand the potential risks before investing.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
CEOs Directory
Screen CEOs from public companies around the world
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Fundamental Analysis
View fundamental data based on most recent published financial statements
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine